secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000784199-22-000157
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q2 revenue $80.3M (+6% GAAP, +9% CC); net loss widens to $4.3M
-----------------------------------------------------------------------

- Revenue $80.3M vs $76.1M YoY; constant currency growth of 9%.
- GAAP net loss $4.3M ($0.11/sh) vs $2.2M ($0.06) YoY; non-GAAP net loss $1.3M ($0.03).
- Aortic stent graft revenue up 23% CC; On-X revenue up 12% CC; Asia Pacific +38% CC.
- Full-year 2022 constant currency revenue growth guidance reaffirmed at 9%-11%.
- Enrolled first patients in US AMDS clinical trial (PERSEVERE); expects FDA PMA approvals for PROACT Mitral and PerClot this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419922000157/0000784199-22-000157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419922000157/aort-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000784199-22-000157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer